Validation of the Italian version of the PSP Quality of Life questionnaire.
Clinical trials
Parkinsonism
Progressive supranuclear palsy
Quality of life
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
29
03
2019
accepted:
10
07
2019
pubmed:
28
7
2019
medline:
28
4
2020
entrez:
28
7
2019
Statut:
ppublish
Résumé
Progressive supranuclear palsy (PSP) is a rare rapidly progressive, neurodegenerative disease characterized by falls and ocular movement disturbances. The use of health-related quality of life (HR-QoL) measures allows assessing changes in health status induced by therapeutic interventions or disease progress in neurodegenerative diseases. The PSP-QoL is a 45-item, self-administered questionnaire designed to evaluate HR-QoL in PSP. Here, the PSP-QoL was translated into Italian and validated in 190 PSP (96 women and 94 men; mean age ± standard deviation, 72 ± 6.5; mean disease duration, 4.2 ± 2.3) patients diagnosed according to the Movement Disorder Society criteria and recruited in 16 third level movement disorders centers participating in the Neurecanet project. The mean PSP-QoL total score was 77.8 ± 37 (physical subscore, 46.5 ± 18.7; mental subscore, 33.6 ± 19.2). The internal consistency was high (Cronbach's alpha = 0.954); corrected item-total correlation was > 0.40 for the majority of items. The significant and moderate correlation of the PSP-QoL with other HR-QoL measures as well as with motor and disability assessments indicated adequate convergent validity of the scale. Gender and geographic location presented a significant impact on the PSP-QoL in our sample with women and patients from the South of Italy scoring higher than their counterparts. In conclusion, the Italian version of the PSP-QoL is an easy, reliable and valid tool for assessment of HR-QoL in PSP.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive supranuclear palsy (PSP) is a rare rapidly progressive, neurodegenerative disease characterized by falls and ocular movement disturbances. The use of health-related quality of life (HR-QoL) measures allows assessing changes in health status induced by therapeutic interventions or disease progress in neurodegenerative diseases. The PSP-QoL is a 45-item, self-administered questionnaire designed to evaluate HR-QoL in PSP.
METHODS AND RESULTS
RESULTS
Here, the PSP-QoL was translated into Italian and validated in 190 PSP (96 women and 94 men; mean age ± standard deviation, 72 ± 6.5; mean disease duration, 4.2 ± 2.3) patients diagnosed according to the Movement Disorder Society criteria and recruited in 16 third level movement disorders centers participating in the Neurecanet project. The mean PSP-QoL total score was 77.8 ± 37 (physical subscore, 46.5 ± 18.7; mental subscore, 33.6 ± 19.2). The internal consistency was high (Cronbach's alpha = 0.954); corrected item-total correlation was > 0.40 for the majority of items. The significant and moderate correlation of the PSP-QoL with other HR-QoL measures as well as with motor and disability assessments indicated adequate convergent validity of the scale. Gender and geographic location presented a significant impact on the PSP-QoL in our sample with women and patients from the South of Italy scoring higher than their counterparts.
CONCLUSION
CONCLUSIONS
In conclusion, the Italian version of the PSP-QoL is an easy, reliable and valid tool for assessment of HR-QoL in PSP.
Identifiants
pubmed: 31350659
doi: 10.1007/s10072-019-04010-2
pii: 10.1007/s10072-019-04010-2
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2587-2594Subventions
Organisme : Neurecanet
ID : NA
Références
Qual Life Res. 2002 May;11(3):193-205
pubmed: 12074258
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Mov Disord. 2018 Aug;33(8):1361-1365
pubmed: 29984518
J Neurol. 2017 Aug;264(8):1583-1607
pubmed: 28054129
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Pharmacoeconomics. 2001;19(7):729-52
pubmed: 11548910
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Neurology. 2006 Jul 11;67(1):39-44
pubmed: 16832075
Neurol Sci. 2019 Oct;40(10):2163-2169
pubmed: 31190253
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801